Abstract
We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode. The authors report the case of a 68-year-old woman who underwent a successful combined heart and kidney transplant for amyloidosis, was then started on lenalidomide therapy, and died 2 weeks later, likely because of lenalidomide-related severe rejection of both organs.
Original language | English (US) |
---|---|
Pages (from-to) | 2730-2733 |
Number of pages | 4 |
Journal | American Journal of Transplantation |
Volume | 13 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2013 |
Externally published | Yes |
Keywords
- Allograft rejection
- amyloidosis
- cardiac transplant
- lenalidomide
- renal transplant
- transplantation
ASJC Scopus subject areas
- Immunology and Allergy
- Transplantation
- Pharmacology (medical)